Navigation Links
Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder
Date:8/26/2014

gly utilized in central nervous system (CNS) clinical trials. This study design is intended to reduce placebo response rates, a phenomenon commonly observed in depression trials.  The primary efficacy measure is the Montgomery-Asberg Depression Rating Scale (MADRS) total score, a standard clinical measure of depression. Secondary outcome measures include assessments of disease severity, activities of daily living, and quality of life. Pharmacokinetics and standard safety assessments will also be conducted.

Update on the Agitation in Alzheimer's Disease Patients Study
The company expects to announce top-line results from the Agitation in Alzheimer's disease study in late September/early October 2014. The objectives of this proof of concept study are to evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment of agitation in Alzheimer's patients. The trial is a 10-week, multicenter, randomized, double-blind, placebo-controlled study utilizing a SPCD design intended to reduce placebo response rates. Enrollment was completed with 220 Alzheimer's patients in the United States. Eligible patients were initially randomized 3:4 to receive either AVP-923 (dose escalated from DM 20mg/ Q 10mg to DM 30mg/ Q 10mg) or placebo. At the end of week five, patients who initially received placebo were stratified according to their response to treatment and subsequently re-randomized 1:1 to receive either AVP-923 or placebo for the remainder of the study (an additional 5 weeks of treatment). Patients who initially received AVP-923 continued to receive AVP-923 DM 30mg/ Q 10mg for the remainder of the study. The main efficacy measure is the agitation/aggression subscale of the Neuropsychiatric Inventory or NPI. The primary endpoint follows a standard analysis of SPCD by combining the change from baseline to week 5 (full analysis population) and change from week 5 to week 10 on the NPI agitation/aggression domain (patients who we
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
2. Avanir Pharmaceuticals to Participate in Two Conferences in August
3. Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder
4. Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study
5. Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
6. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
7. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
8. Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
9. Avanir Pharmaceuticals Announces Results for Phase II PRIME Study
10. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... NEW YORK , March 4, 2015 /PRNewswire/ ... orthopedic device market is the increasing elderly population, ... in a recent report from the healthcare market ... aging population coupled with other risk factors such ... orthopedic incidence worldwide. Demand for innovative product designs ...
(Date:3/4/2015)... ATLANTA, March 4, 2015 Alimera Sciences, ... pharmaceutical company that specializes in the research, development ... financial results for the fourth quarter and year ... year was a pivotal year for Alimera Sciences, ... ILUVIEN in September for the treatment of diabetic ...
(Date:3/4/2015)... MARLTON, N.J. , March 4, 2015 ... brand protection and serialization solutions, announced it will be ... Roosevelt Paper. The live event, "How to Boost Manufacturing ... on Wednesday, March 18th at 2:00 PM EDT.  ... Officer for Acsis, and John Gordon , Chief ...
Breaking Medicine Technology:Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 2Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 3Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 4Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 5Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 6Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 7Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 8Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 9Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 10Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 11Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 12Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 13Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 14
... STXS ) continued leadership in the remote ... again be prominently detailed in the scientific program of ... Francisco, California. Ten podium presentations and ten posters will ... magnetic navigation in the treatment of a variety of ...
... HAYWARD, Calif., May 3, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... highlights for the quarter ended March 31, 2011. ... the first quarter ended March 31, 2011 were $18.7 million, ... 2010. The increased operating expenses in the first quarter of ...
Cached Medicine Technology:Stereotaxis' Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011 2Stereotaxis' Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011 3Stereotaxis' Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011 4Stereotaxis' Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011 5Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update 5
(Date:3/5/2015)... In recognition of its ongoing commitment ... Flordis International (SFI) has been honored by the American ... natural medicine company committed to identifying and developing natural ... and effectiveness. For these efforts the non-profit ABC selected ... in Phytomedicinal Research Award. , Phytomedicinal research seeks ...
(Date:3/5/2015)... 05, 2015 March is National ... campaign sponsored by the Academy of Nutrition and ... Healthy Lifestyle," which promotes the consumption of fewer ... achieving and maintaining a healthy weight, reducing risks ... , Whether a person is new to physical ...
(Date:3/5/2015)... GA (PRWEB) March 05, 2015 The ... Fu for Health and Wellness at Atlanta Shaolin Institute ... on 4350 Peachtree Industrial BLVD, Suite 500A, city of ... (Shaolin Chan Foundation), which is a non-profit organization that ... arts, philosophy and medicine. , The seminar was ...
(Date:3/5/2015)... March 05, 2015 Medical professionals suggest ... here—and it’s a crisis that is worsening. The demand ... order to stay on top of the physician shortage, ... PracticeLink to meet face-to-face with physicians and advanced practitioners ... and Job Fair series. , Physician openings take an ...
(Date:3/4/2015)... (PRWEB) March 05, 2015 Understanding China’s ... — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/UnderstandingChinaMDRegs ... and revamped regulations for medical devices in China. ... medical devices — research and development, approval, manufacturing, distribution, ... — those currently in development as well as those ...
Breaking Medicine News(10 mins):Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 2Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 3Health News:National Nutrition Month® Tips for Athletes from the Austin Sports Medicine Team at Medicine in Motion 2Health News:National Nutrition Month® Tips for Athletes from the Austin Sports Medicine Team at Medicine in Motion 3Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 2Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 3Health News:Physician Shortage Crisis Worsening 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 3
... First-of-Its-Kind Device To Aid Dentists & Doctors in Detecting Oral ... More Deadly Than Breast, Cervical, or Prostate Cancers , HOUSTON, ... to aid in early detection, dentists, hygienists, and doctors have ... -- oral cancer , ...
... Pharmaceuticals USA, the leading generic pharmaceutical company, today ... to push for more affordable healthcare. The program, ... 25th anniversary of the landmark Waxman-Hatch Act which ... resulted in billions of dollars of savings."With a ...
... Service Corporation,International (NYSE: SCI ), which ... that its Board of Directors has approved a,quarterly cash ... The,quarterly cash dividend announced today is payable on ... of business on April 15, 2009. While the,Company ...
... new biological marker present in the urine of patients ... progressing and spreading. , In experiments reported in the ... the scientists identified 10 metabolites that become more ... showed that one of these chemicals, sarcosine, helps prostate ...
... 11 This Valentine,s Day, Berry Chill is,offering a ... any chilled yogurt,order, they,ll receive a free Valentine,s Day ... with fresh strawberries, pomegranate and,chocolate chips. , ... and the pair must,place the order together. Subtractions from ...
... Feb. 11 ActivCore LLC, a,leading company ... Redcord,products in the United States, announces the ... (WIM). ActivCore will leverage WIM,s training,infrastructure ... will serve,therapy professionals, chiropractors, fitness club professionals, ...
Cached Medicine News:Health News:New Identafi(TM) 3000 Identifies Signs of Silent Killer: 2Health News:New Identafi(TM) 3000 Identifies Signs of Silent Killer: 3Health News:New Identafi(TM) 3000 Identifies Signs of Silent Killer: 4Health News:Teva Launches National Advocacy Campaign for Affordable Healthcare 2Health News:Service Corporation International Declares Quarterly Cash Dividend 2Health News:Service Corporation International Declares Quarterly Cash Dividend 3Health News:Survey of metabolites finds new prostate cancer marker 2Health News:Survey of metabolites finds new prostate cancer marker 3Health News:Berry Chill Offers Sweet Valentine's Day Deal for Couples 2Health News:ActivCore LLC Announces Strategic Partnership with Wellness in Motion 2
Used to establish and temporarily maintain suprapubic access during endoscopic procedures. Supplied sterile in peel-open packages. Intended for one-time use....
... is a minimally invasive tension-free sling ... incontinence resulting from urethral hypermobility (Type ... Stratasis TF Kit is designed to ... placement. Supplied sterile in peel-open ...
... a Roadrunner, Bentson, or other flexible tipped ... beyond a redundant or tortuous ureteral segment. ... around and beyond a ureteral stone, or ... stone from the mucosal wall. Supplied sterile ...
... of contrast medium, anesthetic gel, and/or safety ... the need for multiple catheterizations. The Flexi-Tip ... into and through the ureter. AQ is ... when activated, attracts and holds water and ...
Medicine Products: